HOME > Investors >
Press Releases
2018-07-30
ViroMed Announces Publication on VM202’s MoA in Regulating Muscle Atrophy
2018-07-26
Last Patient Randomized in ViroMed’s VM202 Phase III Trial on PDPN
2018-07-05
Drug based on ViroMed’s VM202 Technology Successfully Completes Phase II for CLI in China
2018-07-02
2018.06(IR letter) BusinessUpdates
2018-05-30
ViroMed Announces Publication of VM202’s MoA in Nerve Regeneration
1
2
3
4
5
6
7
8
9
10
